{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:34:27Z","timestamp":1790714067079,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd015364","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000}}],"reference-count":420,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015364.pub2","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T02:18:51Z","timestamp":1763950731000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis"],"prefix":"10.1002","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5449-6844","authenticated-orcid":false,"given":"Hanna","family":"Bergman","sequence":"additional","affiliation":[{"name":"Cochrane Response; The Cochrane Collaboration; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Henschke","sequence":"additional","affiliation":[{"name":"Cochrane Response; The Cochrane Collaboration; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Arevalo-Rodriguez","sequence":"additional","affiliation":[{"name":"Cochrane Response; The Cochrane Collaboration; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S","family":"Buckley","sequence":"additional","affiliation":[{"name":"Cochrane Response; The Cochrane Collaboration; London UK"},{"name":"Department of Surgery; University of the Philippines; Manila Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma J","family":"Crosbie","sequence":"additional","affiliation":[{"name":"Division of Cancer Sciences, Faculty of Biology, Medicine and Health; University of Manchester; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer C","family":"Davies","sequence":"additional","affiliation":[{"name":"Division of Cancer Sciences, Faculty of Biology, Medicine and Health; University of Manchester; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Dwan","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination; University of York; York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su P","family":"Golder","sequence":"additional","affiliation":[{"name":"Department of Health Sciences; University of York; York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Kong","family":"Loke","sequence":"additional","affiliation":[{"name":"Norwich Medical School; University of East Anglia; Norwich UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Probyn","sequence":"additional","affiliation":[{"name":"Cochrane Response; The Cochrane Collaboration; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Petkovic","sequence":"additional","affiliation":[{"name":"Cochrane Response; The Cochrane Collaboration; London UK"},{"name":"Bruy\u00e8re Research Institute; University of Ottawa; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Villanueva","sequence":"additional","affiliation":[{"name":"Cochrane Response; The Cochrane Collaboration; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Morrison","sequence":"additional","affiliation":[{"name":"Department of Gynaecological Oncology; Musgrove Park Hospital; Taunton UK"},{"name":"Faculty of Health and Life Sciences; University of Exeter; Exeter, Devon UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"e61825","DOI":"10.1371\/journal.pone.0061825","article-title":"A randomized, observer-blinded immunogenicity trial of Cervarix and Gardasil human papillomavirus vaccines in 12-15 year old girls","volume":"8","author":"Draper","year":"2013","journal-title":"PloS One"},{"issue":"6","key":"10.1002\/14651858.CD015364.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2016.1277846","article-title":"Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females","volume":"13","author":"Haskins-Coulter","year":"2017","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"10","key":"10.1002\/14651858.CD015364.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years","volume":"5","author":"Einstein","year":"2009","journal-title":"Human Vaccines"},{"issue":"12","key":"10.1002\/14651858.CD015364.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4161\/hv.7.12.18281","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 vaccine and HPV-6\/11\/16\/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years","volume":"7","author":"Einstein","year":"2011","journal-title":"Human Vaccines"},{"issue":"12","key":"10.1002\/14651858.CD015364.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.4161\/hv.36117","article-title":"Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study","volume":"10","author":"Einstein","year":"2015","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"12","key":"10.1002\/14651858.CD015364.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.4161\/hv.36121","article-title":"Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial","volume":"10","author":"Einstein","year":"2014","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0007|cit7","unstructured":"Clinical study report: immunogenicity of GlaxoSmithKline Biological\u2019s human papillomavirus (HPV) vaccine (580299) versus Merck\u2019s Gardasil\u00ae in healthy females 18-45 years of age Available from: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=108933 (accessed on 03 October 2022)"},{"issue":"3","key":"10.1002\/14651858.CD015364.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1080\/21645515.2015.1011570","article-title":"The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine","volume":"11","author":"Gilca","year":"2015","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0009|cit9","unstructured":"Clinical study report: immunogenicity and safety study of GlaxoSmithKline Biologicals' human papillomavirus (HPV) vaccine (GSK-580299) and Merck's Gardasil vaccine when administered according to alternative 2-dose schedules in 9-14 year old females Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=115411 (accessed on 03 October 2022)"},{"issue":"7","key":"10.1002\/14651858.CD015364.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1080\/21645515.2015.1050570","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 as04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: results to month 12 from a randomized trial","volume":"11","author":"Leung","year":"2015","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.vaccine.2017.11.034","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: results to month 36 from a randomized trial","volume":"36","author":"Leung","year":"2018","journal-title":"Vaccine"},{"issue":"34","key":"10.1002\/14651858.CD015364.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1016\/j.vaccine.2013.06.034","article-title":"A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18-26 years","volume":"31","author":"Nelson","year":"2013","journal-title":"Vaccine"},{"issue":"3","key":"10.1002\/14651858.CD015364.pub2-BIB0013|cit13","first-page":"437","article-title":"Comparison of post-licensure safety surveillance of bivalent and quadrivalent human papillomavirus vaccines in healthy Mumbai women","volume":"7","author":"Sangar","year":"2015","journal-title":"International Journal of Pharmacy and Pharmaceutical Sciences"},{"issue":"10","key":"10.1002\/14651858.CD015364.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"e1473","DOI":"10.1016\/S2214-109X(22)00309-6","article-title":"Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial","volume":"10","author":"Watson-Jones","year":"2022","journal-title":"Lancet Global Health"},{"issue":"46","key":"10.1002\/14651858.CD015364.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1016\/j.vaccine.2018.09.057","article-title":"Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - a randomized clinical trial","volume":"36","author":"Gilca","year":"2018","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"EVIDoa2100056","DOI":"10.1056\/EVIDoa2100056","article-title":"Efficacy of single-dose HPV vaccination among young African women","volume":"1","author":"Barnabas","year":"2022","journal-title":"NEJM Evidence"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1447-0756.2009.01167.x","article-title":"Immunogenicity and safety of human papillomavirus-16\/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women","volume":"36","author":"Bhatla","year":"2010","journal-title":"Journal of Obstetrics and Gynaecology Research"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0018|cit18","unstructured":"Clinical study report: evaluation of the immune and safety response of GlaxoSmithKline (GSK) Biologicals' HPV vaccine in healthy Indian women Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=104479 (accessed on 04 October 2022)"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jcv.2016.09.011","article-title":"Effectiveness of HPV vaccination in women reaching screening age in Italy","volume":"84","author":"Carozzi","year":"2016","journal-title":"Journal of Clinical Virology"},{"issue":"7","key":"10.1002\/14651858.CD015364.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.4161\/hv.24337","article-title":"Evaluation of bivalent human papillomavirus (HPV) vaccine safety and tolerability in a sample of 25 year old Tuscan women","volume":"9","author":"Levi","year":"2013","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"djv302","DOI":"10.1093\/jnci\/djv302","article-title":"Multisite HPV16\/18 vaccine efficacy against cervical, anal, and oral HPV infection","volume":"108","author":"Beachler","year":"2015","journal-title":"Journal of the National Cancer Institute"},{"issue":"6","key":"10.1002\/14651858.CD015364.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/infdis\/jiv519","article-title":"Cross-protection of the bivalent human papillomavirus (HPV) vaccine against variants of genetically related high-risk HPV infections","volume":"213","author":"Harari","year":"2016","journal-title":"Journal of Infectious Diseases"},{"issue":"37","key":"10.1002\/14651858.CD015364.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1016\/j.vaccine.2008.07.002","article-title":"Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica","volume":"26","author":"Herrero","year":"2008","journal-title":"Vaccine"},{"issue":"7","key":"10.1002\/14651858.CD015364.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"e68329","DOI":"10.1371\/journal.pone.0068329","article-title":"Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica","volume":"8","author":"Herrero","year":"2013","journal-title":"PloS One"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2159-8290.CD-11-0131","article-title":"Prevention of persistent human papillomavirus infection by an HPV16\/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica","volume":"1","author":"Herrero","year":"2011","journal-title":"Cancer Discovery"},{"issue":"7","key":"10.1002\/14651858.CD015364.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"issue":"39","key":"10.1002\/14651858.CD015364.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1016\/j.vaccine.2014.06.038","article-title":"Efficacy of the HPV-16\/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16\/18 vaccine trial","volume":"32","author":"Hildesheim","year":"2014","journal-title":"Vaccine"},{"issue":"9","key":"10.1002\/14651858.CD015364.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(11)70213-3","article-title":"Efficacy of a bivalent HPV 16\/18 vaccine against anal HPV 16\/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial","volume":"12","author":"Kreimer","year":"2011","journal-title":"Lancet Oncology"},{"issue":"19","key":"10.1002\/14651858.CD015364.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"Journal of the National Cancer Institute"},{"issue":"12","key":"10.1002\/14651858.CD015364.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/infdis\/jiu357","article-title":"Reduced prevalence of vulvar HPV16\/18 infection among women who received the HPV16\/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial","volume":"210","author":"Lang Kuhs","year":"2014","journal-title":"Journal of Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD015364.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(20)30524-6","article-title":"Efficacy of the bivalent HPV vaccine against HPV 16\/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial","volume":"21","author":"Porras","year":"2020","journal-title":"Lancet Oncology"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/aje\/kwt047","article-title":"Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment","volume":"178","author":"Rodriguez","year":"2013","journal-title":"American Journal of Epidemiology"},{"issue":"8","key":"10.1002\/14651858.CD015364.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/jnci\/djz222","article-title":"Efficacy of the AS04-adjuvanted HPV-16\/18 vaccine: pooled analysis of the Costa Rica Vaccine and PATRICIA randomized controlled trials","volume":"112","author":"Tota","year":"2020","journal-title":"Journal of the National Cancer Institute"},{"issue":"2","key":"10.1002\/14651858.CD015364.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jadohealth.2009.11.205","article-title":"Immunogenicity and safety of human papillomavirus-16\/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women","volume":"46","author":"Garcia-Sicilia","year":"2010","journal-title":"Journal of Adolescent Health"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0035|cit35","unstructured":"Clinical study report: evaluation of safety and immunogenicity of co-administering human papillomavirus (HPV) vaccine with other vaccines in healthy female subjects Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=108464 (accessed on 04 October 2022)"},{"issue":"38","key":"10.1002\/14651858.CD015364.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1016\/j.vaccine.2010.07.007","article-title":"Sustained efficacy and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women","volume":"28","author":"De Carvalho","year":"2010","journal-title":"Vaccine"},{"issue":"9706","key":"10.1002\/14651858.CD015364.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years","volume":"374","author":"Romanowski","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0038|cit38","unstructured":"Clinical study report: efficacy study of HPV-16\/18 vaccine (GSK 580299) to prevent HPV-16 and\/or -18 cervical infection in young healthy women Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=580299\/001 (accessed on 04 October 2022)"},{"issue":"9447","key":"10.1002\/14651858.CD015364.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"9518","key":"10.1002\/14651858.CD015364.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 45 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD015364.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/hv.29532","article-title":"Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination","volume":"10","author":"Naud","year":"2014","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"3","key":"10.1002\/14651858.CD015364.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4161\/hv.18865","article-title":"Sustained immunogenicity and efficacy of the HPV-16\/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up","volume":"8","author":"Roteli-Martins","year":"2012","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"8","key":"10.1002\/14651858.CD015364.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1055\/s-0037-1604133","article-title":"Detection of high-risk human papillomavirus in cervix sample in an 11.3-year follow-up after vaccination against HPV 16\/18","volume":"39","author":"Teixeira","year":"2017","journal-title":"Revista Brasileira de Ginecologia e Obstetricia"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Choudhury S Hussain S Ferdous J Hossain F Begum SR Jahan M Safety and immunogenicity profile of human papilloma virus 16\/18-AS04 adjuvant cervical cancer vaccine in healthy adolescent girls of Bangladesh European Journal of Cancer 2011 S541","DOI":"10.1016\/S0959-8049(11)72135-9"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"S371","DOI":"10.1016\/S0020-7292(12)60745-0","article-title":"Safety and immunogenicity profile of human papillomavirus vaccine in adolescent girls of Bangladesh","volume":"119","author":"Hossain","year":"2012","journal-title":"International Journal of Gynaecology and Obstetrics"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/jjco\/hyr173","article-title":"Safety and immunogenicity profile of human papillomavirus-16\/18 AS04 adjuvant cervical cancer vaccine: a randomized controlled trial in healthy adolescent girls of Bangladesh","volume":"42","author":"Khatun","year":"2012","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0047|cit47","unstructured":"Clinical study report: evaluate the immunogenicity & safety of GSK Biologicals' HPV vaccine in female subjects aged 10-14 years Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=104951 (accessed on 04 October 2022)"},{"issue":"8","key":"10.1002\/14651858.CD015364.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3346\/jkms.2010.25.8.1197","article-title":"Vaccination with a human papillomavirus (HPV)-16\/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years","volume":"25","author":"Kim","year":"2010","journal-title":"Journal of Korean Medical Science"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0049|cit49","unstructured":"Clinical study report: a study to evaluate the immune response and safety of GSK Biologicals' HPV-16\/18 L1 VLP AS04 vaccine\/Cervarix TM vaccine in healthy females aged 15-25 years Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=107291 (accessed on 04 October 2022)"},{"issue":"2","key":"10.1002\/14651858.CD015364.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3802\/jgo.2011.22.2.67","article-title":"Human papillomavirus 16\/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women","volume":"22","author":"Kim","year":"2011","journal-title":"Journal of Gynecologic Oncology"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0051|cit51","unstructured":"Clinical study report: human papillomavirus (HPV) vaccine (Cervarix TM) efficacy, immunogenicity & safety trial in adult Japanese women with GSK Biologicals HPV-16\/18 vaccine Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=104798 (accessed on 04 October 2022)"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/IGC.0b013e3181a23c0e","article-title":"Immunogenicity, reactogenicity, and safety of human papillomavirus 16\/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7","volume":"19","author":"Konno","year":"2009","journal-title":"International Journal of Gynecological Cancer"},{"issue":"3","key":"10.1002\/14651858.CD015364.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/IGC.0b013e3181d373a5","article-title":"Efficacy of human papillomavirus 16\/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized, controlled trial","volume":"20","author":"Konno","year":"2010","journal-title":"International Journal of Gynecological Cancer"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/IGC.0b013e3181da2128","article-title":"Efficacy of human papillomavirus type 16\/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years","volume":"20","author":"Konno","year":"2010","journal-title":"International Journal of Gynecological Cancer"},{"issue":"4","key":"10.1002\/14651858.CD015364.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1349-7006.2011.01878.x","article-title":"Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study","volume":"102","author":"Konno","year":"2011","journal-title":"Cancer Science"},{"issue":"7","key":"10.1002\/14651858.CD015364.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.4161\/hv.28712","article-title":"Efficacy of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women: open follow-up of a randomized clinical trial up to 4 years post-vaccination","volume":"10","author":"Konno","year":"2014","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"6","key":"10.1002\/14651858.CD015364.pub2-BIB0057|cit57","first-page":"1","article-title":"Safety of the AS04-adjuvanted human papillomavirus (HPV)-16\/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years","volume":"16","author":"Bi","year":"2019","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0058|cit58","unstructured":"Clinical study report: effectiveness, safety and immunogenicity of GSK biologicals' HPV vaccine GSK580299 (cervarix) administered in healthy adolescents Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=106636 (accessed on 03 October 2022)"},{"issue":"3","key":"10.1002\/14651858.CD015364.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/ijc.32189","article-title":"Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV)","volume":"145","author":"Gray","year":"2019","journal-title":"International Journal of Cancer"},{"issue":"12","key":"10.1002\/14651858.CD015364.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1002\/ijc.31281","article-title":"Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females - post-hoc analysis of a community-randomized clinical trial (II)","volume":"142","author":"Gray","year":"2018","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"106473","DOI":"10.1016\/j.ypmed.2021.106473","article-title":"Preterm birth rate after bivalent HPV vaccination: registry-based follow-up of a randomized clinical trial","volume":"146","author":"Kalliala","year":"2021","journal-title":"Preventive Medicine"},{"issue":"10","key":"10.1002\/14651858.CD015364.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.vaccine.2014.12.019","article-title":"Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial","volume":"33","author":"Lehtinen","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/ijc.32791","article-title":"Effectiveness of the AS04-adjuvanted HPV-16\/18 vaccine in reducing oropharyngeal HPV infections in young females - results from a community-randomized trial","volume":"147","author":"Lehtinen","year":"2019","journal-title":"International Journal of Cancer"},{"issue":"21","key":"10.1002\/14651858.CD015364.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"7759\u201371","DOI":"10.1002\/cam4.4299","article-title":"Effectiveness of various human papillomavirus vaccination strategies: a community randomized trial in Finland","volume":"10","author":"Lehtinen","year":"2021","journal-title":"Cancer Medicine"},{"issue":"12","key":"10.1002\/14651858.CD015364.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1080\/21645515.2016.1183847","article-title":"Safety of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: interim analysis of a large community-randomized controlled trial","volume":"12","author":"Lehtinen","year":"2016","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"9","key":"10.1002\/14651858.CD015364.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/ijc.31618","article-title":"Gender-neutral vaccination provides improved control of human papillomavirus types 18\/31\/33\/35 through herd immunity: results of a community randomized trial (III)","volume":"143","author":"Lehtinen","year":"2018","journal-title":"International Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/ijc.31119","article-title":"Impact of gender-neutral or girls-only vaccination against human papillomavirus - results of a community-randomized clinical trial (I)","volume":"142","author":"Lehtinen","year":"2018","journal-title":"International Journal of Cancer"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015364.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"A44","DOI":"10.1136\/sextrans-2013-051184.0138","article-title":"A community-randomised phase IV human papillomavirus (HPV) vaccination trial of vaccination strategy","volume":"89","author":"Paavonen","year":"2013","journal-title":"Sexually Transmitted Infections"},{"issue":"6","key":"10.1002\/14651858.CD015364.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/infdis\/jiaa099","article-title":"Vaccination with moderate coverage eradicates oncogenic human papillomaviruses if a gender-neutral strategy is applied","volume":"222","author":"Vanska","year":"2020","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0070|cit70","unstructured":"Clinical study report: immunogenicity and safety of a commercially available vaccine co-administered with GSK HPV vaccine (580299) Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=111567 (accessed on 04 October 2022)"},{"issue":"9","key":"10.1002\/14651858.CD015364.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1128\/CVI.00539-10","article-title":"Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16\/18 AS04-adjuvanted cervical cancer vaccine","volume":"18","author":"Leroux-Roels","year":"2011","journal-title":"Clinical and Vaccine Immunology"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0072|cit72","unstructured":"Clinical study report: study to evaluate the immune response and safety of GSK Biologicals' HPV vaccine in healthy women aged 18-35 years Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=105926 (accessed on 04 October 2022)"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0073|cit73","first-page":"2","article-title":"Immunogenicity and safety of the AS04-adjuvanted human papillomavirus-16\/18 cervical cancer vaccine in Malaysian women aged 18-35 years: a randomized controlled trial","volume":"69","author":"Lim","year":"2014","journal-title":"Medical Journal of Malaysia"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0074|cit74","unstructured":"Clinical study report: safety and immunogenicity of GSK Biologicals\u2019 HPV-16\/18 L1 VLP AS04 vaccine (GSK-580299) in healthy female children 4-6 years old Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=115887 (accessed on 04 October 2022)"},{"issue":"10","key":"10.1002\/14651858.CD015364.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/INF.0000000000002437","article-title":"Long-term immunogenicity and safety of the AS04-adjuvanted human papillomavirus-16\/18 vaccine in four- to six-year-old girls: three-year follow-up of a randomized phase III trial","volume":"38","author":"Lin","year":"2019","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"4","key":"10.1002\/14651858.CD015364.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1097\/INF.0000000000001871","article-title":"Safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine in 4-6-year-old girls: results to month 12 from a randomized trial","volume":"37","author":"Lin","year":"2018","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"4","key":"10.1002\/14651858.CD015364.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1097\/INF.0000000000001871","article-title":"Safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine in 4-6-year-old girls: results to month 12 from a randomized trial","volume":"37","author":"Lin","year":"2018","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0078|cit78","unstructured":"Clinical study report: human papillomavirus vaccine safety and immunogenicity trial in young adolescent women with GSK Bio HPV-16\/18 Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=580299\/013 (accessed on 04 October 2022)"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jadohealth.2010.02.006","article-title":"Safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls","volume":"46","author":"Medina","year":"2010","journal-title":"Journal of Adolescent Health"},{"issue":"2","key":"10.1002\/14651858.CD015364.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jadohealth.2011.11.004","article-title":"Four-year follow-up of the immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years","volume":"50","author":"Schwarz","year":"2012","journal-title":"Journal of Adolescent Health"},{"issue":"12","key":"10.1002\/14651858.CD015364.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1097\/INF.0000000000000460","article-title":"Long-term immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial","volume":"33","author":"Schwarz","year":"2014","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0082|cit82","unstructured":"Clinical study report: a study to evaluate the immunogenicity and safety of GSK Biologicals' HPV vaccine in healthy women aged 18-35 years Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=106001 (accessed on 04 October 2022)"},{"issue":"3","key":"10.1002\/14651858.CD015364.pub2-BIB0083|cit83","first-page":"171","article-title":"Human papillomavirus-16\/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong","volume":"16","author":"Ngan","year":"2010","journal-title":"Xianggang Yi Xue za Zhi [Hong Kong Medical Journal]"},{"issue":"4","key":"10.1002\/14651858.CD015364.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/CVI.00591-14","article-title":"Efficacy of human papillomavirus 16 and 18 (HPV-16\/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial","volume":"22","author":"Apter","year":"2015","journal-title":"Clinical and Vaccine Immunology"},{"issue":"2","key":"10.1002\/14651858.CD015364.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"JC2-7","DOI":"10.7326\/0003-4819-157-2-201207170-02007","article-title":"HPV-16\/18 AS04-adjuvanted vaccine prevented cervical intraepithelial neoplasia > grade 3 in young women","volume":"157","author":"Budenholzer","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1586\/14737140.8.5.701","article-title":"Evaluation of the interim analysis from the PATRICIA study group: efficacy of a vaccine against HPV 16 and 18","volume":"8","author":"Frederick","year":"2008","journal-title":"Expert Review of Anticancer Therapy"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0087|cit87","doi-asserted-by":"crossref","unstructured":"Garland S Paavonen J Teixeira J Hedrick J Struyf F Dubin G Cross-protective efficacy of Cervarix against HPV-45 in a double blind randomized controlled Phase III efficacy trial International Journal of Gynaecology and Obstetrics 2009 S188","DOI":"10.1016\/S0020-7292(09)60706-2"},{"issue":"6 Suppl 2","key":"10.1002\/14651858.CD015364.pub2-BIB0088|cit88","first-page":"S110","article-title":"Efficacy of the HPV-16\/18 AS04-adjuvanted vaccine against vulvar\/vaginal intraepithelial neoplasia","volume":"17","author":"Garland","year":"2013","journal-title":"Journal of Lower Genital Tract Disease"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0089|cit89","unstructured":"Clinical study report: human papillomavirus (HPV) vaccine efficacy trial against cervical pre-cancer in young adults with GlaxoSmithKline (GSK) Biologicals HPV-16\/18 Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=580299\/008 (accessed on 04 October 2022)"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncology"},{"issue":"9580","key":"10.1002\/14651858.CD015364.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet (London, England)"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015364.pub2-BIB0092|cit92","first-page":"A71","article-title":"Long-term efficacy of human papillomavirus vaccination against CIN3 and invasive cervical carcinoma: a registry based passive follow-up of the phase III trial (PATRICIA)","volume":"87","author":"Paavonen","year":"2011","journal-title":"Sexually Transmitted Infections"},{"issue":"9686","key":"10.1002\/14651858.CD015364.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet (London, England)"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015364.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"A54","DOI":"10.1136\/sextrans-2013-051184.0165","article-title":"Occurrence of vaccine and non-vaccine human papillomavirus (HPV) types in the female population before and after the HPV vaccination","volume":"89","author":"Paavonen","year":"2013","journal-title":"Sexually Transmitted Infections"},{"issue":"12","key":"10.1002\/14651858.CD015364.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1002\/ijc.27586","article-title":"Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination","volume":"131","author":"Palmroth","year":"2012","journal-title":"International Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD015364.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1128\/CVI.00457-14","article-title":"Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)\/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA","volume":"22","author":"Struyf","year":"2015","journal-title":"Clinical and Vaccine Immunology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015364.pub2-BIB0097|cit97","first-page":"S353","article-title":"Cross-protective efficacy of Cervarix against oncogenic types beyond HPV-16\/18: analysis of the according-to-protocol (atp) cohort in a double blind, randomized controlled Phase III efficacy trial","volume":"107","author":"Szarewski","year":"2009","journal-title":"International Journal of Gynecology and Obstetrics."},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/ijc.26362","article-title":"Efficacy of the human papillomavirus (HPV)-16\/18 ASO4-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16\/18","volume":"131","author":"Szarewski","year":"2012","journal-title":"International Journal of Cancer"},{"issue":"9","key":"10.1002\/14651858.CD015364.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/infdis\/jit360","article-title":"Efficacy of the HPV-16\/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation","volume":"208","author":"Szarewski","year":"2013","journal-title":"Journal of Infectious Diseases"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD015364.pub2-BIB0100|cit100","first-page":"S16 Abstract 35","article-title":"Efficacy of the AS04 -adjuvanted HPV-16\/18 vaccine in reduction of abnormal cytology, colposcopy referrals and cervical excision therapies: PATRICIA end-of-study results","volume":"120","author":"Wheeler","year":"2011","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 ASO4-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV-types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0102|cit102","unstructured":"Clinical study report: evaluation of safety and immunogenicity of co-administering human papillomavirus vaccine with another vaccine in healthy female subjects Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=110886 (accessed on 04 October 2022)"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jadohealth.2011.10.009","article-title":"Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16\/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls","volume":"50","author":"Pedersen","year":"2012","journal-title":"Journal of Adolescent Health"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0104|cit104","unstructured":"Clinical study report: evaluation of the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV vaccine in young males Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=580299\/011 (accessed on 03 October 2022)"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jadohealth.2008.10.002","article-title":"Immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years","volume":"44","author":"Petaja","year":"2009","journal-title":"Journal of Adolescent Health"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0106|cit106","unstructured":"Clinical study report: partially blind study to evaluate immunogenicity & safety of GSK Bio's HPV vaccine 580299 in healthy women aged 9-25 yrs Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=110659 (accessed on 04 October 2022)"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/21645515.2015.1065363","article-title":"Sustained immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study","volume":"12","author":"Romanowski","year":"2016","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.4161\/hv.28022","article-title":"Immune response to the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study","volume":"10","author":"Romanowski","year":"2014","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"12","key":"10.1002\/14651858.CD015364.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4161\/hv.7.12.18322","article-title":"Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study","volume":"7","author":"Romanowski","year":"2011","journal-title":"Human Vaccines"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"S476","DOI":"10.1016\/S0020-7292(12)61038-8","article-title":"Immune response to the hpv-16\/18 as04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 3 years after vaccination","volume":"119","author":"Schwarz","year":"2012","journal-title":"International Journal of Gynaecology and Obstetrics"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0111|cit111","unstructured":"Clinical study report: evaluation of immunogenicity and safety of human papillomavirus (HPV) vaccine co-administered with another vaccine in healthy female subjects Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=111507 (accessed on 04 October 2022)"},{"issue":"49","key":"10.1002\/14651858.CD015364.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"9276","DOI":"10.1016\/j.vaccine.2011.08.037","article-title":"Co-administration of human papillomavirus-16\/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls","volume":"29","author":"Schmeink","year":"2011","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0113|cit113","unstructured":"Clinical study report: immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals\u2019 human papillomavirus (HPV) vaccine (GSK580299) in healthy female subjects 10-25 years of age Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=106069 (accessed on 04 October 2022)"},{"issue":"11","key":"10.1002\/14651858.CD015364.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/infdis\/jis619","article-title":"Safety and immunogenicity of human papillomavirus-16\/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women","volume":"207","author":"Sow","year":"2013","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0115|cit115","unstructured":"Clinical study report: study to evaluate the efficacy of the human papillomavirus vaccine in healthy adult women of 26 years of age and older Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=104820 (accessed on 04 October 2022)"},{"issue":"9961","key":"10.1002\/14651858.CD015364.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(14)60920-X","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"384","author":"Skinner","year":"2014","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD015364.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1154\u201368","DOI":"10.1016\/S1473-3099(16)30120-7","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"16","author":"Wheeler","year":"2016","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0118|cit118","unstructured":"Clinical study report: efficacy, immunogenicity and safety of GSK Biologicals\u2019 HPV GSK 580299 vaccine in healthy Chinese female subjects Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=107638 (accessed on 04 October 2022)"},{"issue":"4","key":"10.1002\/14651858.CD015364.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/21645515.2020.1829411","article-title":"Efficacy of the AS04-adjuvanted HPV-16\/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial","volume":"17","author":"Hu","year":"2020","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"9 Suppl 4","key":"10.1002\/14651858.CD015364.pub2-BIB0120|cit120","first-page":"1584","article-title":"Efficacy, safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine in chinese women: 4-year follow-up results from a randomized controlled trial","volume":"24","author":"Zhu","year":"2014","journal-title":"International Journal of Gynecological Cancer"},{"issue":"14","key":"10.1002\/14651858.CD015364.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1002\/cam4.2399","article-title":"Efficacy, immunogenicity and safety of the AS04-HPV-16\/18 vaccine in Chinese women aged 18-25A years: end-of-study results from a phase II\/III, randomised, controlled trial","volume":"8","author":"Hong","year":"2019","journal-title":"Cancer Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/cam4.869","article-title":"Efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial","volume":"6","author":"Hong","year":"2017","journal-title":"Cancer Medicine"},{"issue":"11","key":"10.1002\/14651858.CD015364.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/ijc.28897","article-title":"Efficacy, immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial","volume":"135","author":"Zhu","year":"2014","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0124|cit124","unstructured":"Clinical study report: immunogenicity and safety study of GSK Biologicals\u2019 human papillomavirus 580299 vaccine in healthy female subjects Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=112022 (accessed on 04 October 2022)"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0125|cit125","unstructured":"Immunogenicity and safety study of GSK biologicals' human papillomavirus 580299 vaccine in healthy female subjects https:\/\/clinicaltrials.gov\/show\/NCT00996125 2009"},{"issue":"11","key":"10.1002\/14651858.CD015364.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/ijc.28897","article-title":"Efficacy, immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial","volume":"135","author":"Zhu","year":"2014","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0127|cit127","unstructured":"Clinical study report: study to assess immune responses and safety of the GSK-580299 vaccine in healthy women (26 to 45 years) Available at: https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=114590 (accessed on 04 October 2022)"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0128|cit128","unstructured":"Study to assess immune responses and safety of the GSK-580299 vaccine in healthy women (26 to 45 years) https:\/\/clinicaltrials.gov\/show\/NCT01277042 2011"},{"issue":"11","key":"10.1002\/14651858.CD015364.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/ijc.28897","article-title":"Efficacy, immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial","volume":"135","author":"Zhu","year":"2014","journal-title":"International Journal of Cancer"},{"issue":"48","key":"10.1002\/14651858.CD015364.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1016\/j.vaccine.2015.08.059","article-title":"Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine","volume":"33","author":"Garland","year":"2015","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0131|cit131","unstructured":"Clinical study report: a phase III randomized, international, placebo-controlled, double-blind clinical trial to study the tolerability and immunogenicity of V503, a multivalent human papillomavirus (HPV) L1 virus-like particle (VLP) vaccine, given to females 12-26 years of age who have previously received GARDASIL (Protocol 006) European Medicines Agency"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"5050-7","DOI":"10.1016\/j.vaccine.2017.07.017","article-title":"Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine","volume":"35","author":"Guevara","year":"2017","journal-title":"Vaccine"},{"issue":"10108","key":"10.1002\/14651858.CD015364.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD015364.pub2-BIB0134|cit134","first-page":"S10","article-title":"End of study efficacy for vulvovaginal disease of a novel 9-valent HPV L1 virus-like particle vaccine in 16-26 year old women","volume":"19","author":"Joura","year":"2015","journal-title":"Journal of Lower Genital Tract Disease"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0135|cit135","first-page":"174","article-title":"End of study efficacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16-26 year old women","volume":"OC6","author":"Joura","year":"2015","journal-title":"EUROGIN 2015 Abstracts: HPV Infection and Related Cancers"},{"issue":"9 Suppl 4","key":"10.1002\/14651858.CD015364.pub2-BIB0136|cit136","first-page":"32","article-title":"Efficacy of a novel 9-valent HPV vaccine against high-grade lesions and cancer in 16-to 26-year-old women","volume":"24","author":"Joura","year":"2014","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0137|cit137","first-page":"59","article-title":"Long-term efficacy and immunogenicity of the 9-valent human papillomavirus vaccine: final analyses of a double-blind, randomized clinical study","volume":"Suppl 4","author":"Joura","year":"2017","journal-title":"International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria."},{"issue":"8","key":"10.1002\/14651858.CD015364.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015364.pub2-BIB0139|cit139","first-page":"35","article-title":"Clinical efficacy and immunogenicity of the nonavalent HPV vaccine","volume":"Conference: 19t","author":"Joura","year":"2016","journal-title":"Acta Cytologica"},{"issue":"6","key":"10.1002\/14651858.CD015364.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/21645515.2015.1012010","article-title":"Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine","volume":"11","author":"Luxembourg","year":"2015","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"54-61","DOI":"10.1016\/j.cct.2016.10.006","article-title":"Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine","volume":"52","author":"Luxembourg","year":"2017","journal-title":"Contemporary Clinical Trials"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD015364.pub2-BIB0142|cit142","first-page":"E270","article-title":"End of study efficacy, immunogenicity and safety of a novel 9-valent HPV l1 virus-like particle vaccine in 16-26 year old women","volume":"131","author":"Bautista","year":"2015","journal-title":"International Journal of Gynaecology and Obstetrics"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0143|cit143","unstructured":"Clinical study report: a randomized, international, double-blinded (with in-house blinding), controlled with Gardasil\u2122, dose-ranging, tolerability, immunogenicity, and efficacy study of a multivalent human papillomavirus (HPV) L1 virus-like particle (VLP) vaccine administered to 16- to 26-year-old women European Medicines Agency"},{"issue":"35","key":"10.1002\/14651858.CD015364.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1016\/j.vaccine.2016.06.056","article-title":"A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men","volume":"34","author":"Van Damme","year":"2016","journal-title":"Vaccine"},{"issue":"9","key":"10.1002\/14651858.CD015364.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/INF.0000000000000773","article-title":"A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil in 9-15 year-old girls","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"19","key":"10.1002\/14651858.CD015364.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1016\/j.vaccine.2020.03.017","article-title":"A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States","volume":"38","author":"Hedrick","year":"2020","journal-title":"Vaccine"},{"issue":"17","key":"10.1002\/14651858.CD015364.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0148|cit148","unstructured":"Clinical study report: a controlled trial to assess the immunogenicity of a 2-dose schedule of human papillomavirus vaccine Health Canada"},{"issue":"2","key":"10.1002\/14651858.CD015364.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/QAI.0000000000000425","article-title":"High HIV, HPV, and STI prevalence among young western cape, south african women: EVRI HIV prevention preparedness trial","volume":"68","author":"Giuliano","year":"2015","journal-title":"Journal of Acquired Immune Deficiency Syndromes (1999)"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/sextrans-2016-053046","article-title":"Patterns of prevalent HPV and STI co-infections and associated factors among HIV-negative young Western Cape, South African women: the EVRI trial","volume":"94","author":"Menezes","year":"2018","journal-title":"Sexually Transmitted Infections"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jinf.2015.10.001","article-title":"Cervical HPV natural history among young western cape, south african women: the randomized control EVRI trial","volume":"72","author":"Sudenga","year":"2016","journal-title":"Journal of Infection"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pvr.2017.02.001","article-title":"HPV serostatus pre- and post-vaccination in a randomized phase II preparedness trial among young Western Cape, South African women: the EVRI trial","volume":"3","author":"Sudenga","year":"2017","journal-title":"Papillomavirus Research"},{"issue":"10","key":"10.1002\/14651858.CD015364.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.ebiom.2015.09.005","article-title":"HPV prophylactic vaccination in males improves the clearance of semen infection","volume":"2","author":"Foresta","year":"2015","journal-title":"EBioMedicine"},{"issue":"19","key":"10.1002\/14651858.CD015364.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0155|cit155","unstructured":"Clinical study report: a study to evaluate the efficacy of quadrivalent HPV (types 6, 11, 16, and 18) L1 virus-like particle (VLP) vaccine in reducing the incidence of HPV 6-, 11-, 16-, and 18-related CIN, AIS, and cervical cancer, and HPV 6-, 11-, 16-, and 18-related external genital warts, VIN, VaIN, vulvar cancer, and vaginal cancer in 16- to 23-year-old women \u2013 the FUTURE I study (females united to unilaterally reduce endo\/ectocervical disease) European Medicines Agency"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015364.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"A53","DOI":"10.1136\/sextrans-2013-051184.0163","article-title":"Long-term efficacy of human papillomavirus vaccination against cervical cancer","volume":"89","author":"Paavonen","year":"2013","journal-title":"Sexually Transmitted Infections"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.vaccine.2007.11.043","article-title":"Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6\/11\/16\/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines","volume":"26","author":"Wheeler","year":"2008","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"c3493","DOI":"10.1136\/bmj.c3493","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"341","author":"FUTURE I\/II Study Group","year":"2010","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Munoz","year":"2010","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"105996","DOI":"10.1016\/j.cct.2020.105996","article-title":"Use of real-world data for HPV vaccine trial follow-up in the Nordic region","volume":"92","author":"Enerly","year":"2020","journal-title":"Contemporary Clinical Trials"},{"issue":"19","key":"10.1002\/14651858.CD015364.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"FUTURE II Study Group","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015364.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/cid\/cix797","article-title":"A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 nordic countries","volume":"66","author":"Kjaer","year":"2018","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"100401","DOI":"10.1016\/j.eclinm.2020.100401","article-title":"Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries","volume":"23","author":"Kjaer","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015364.pub2-BIB0164|cit164","first-page":"A71","article-title":"Long-term efficacy of human papillomavirus vaccination against cin3 and invasive carcinoma: registry based follow-up of a phase III trial (future II)","volume":"87","author":"Paavonen","year":"2011","journal-title":"Sexually Transmitted Infections"},{"issue":"12","key":"10.1002\/14651858.CD015364.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1002\/ijc.27971","article-title":"Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: cancer registry-based follow-up","volume":"132","author":"Rana","year":"2013","journal-title":"International Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age","volume":"105","author":"Castellsague","year":"2011","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"100202","DOI":"10.1016\/j.pvr.2020.100202","article-title":"Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial","volume":"10","author":"Ferris","year":"2020","journal-title":"Papillomavirus Research"},{"issue":"3","key":"10.1002\/14651858.CD015364.pub2-BIB0168|cit168","first-page":"245","article-title":"The effect of quadrivalent HPV (types 6\/11\/16\/18) vaccination on Papanicolaou smears and cervical procedures in women aged 24 to 45","volume":"14","author":"Ferris","year":"2010","journal-title":"Journal of Lower Genital Tract Disease"},{"issue":"12","key":"10.1002\/14651858.CD015364.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"e83431","DOI":"10.1371\/journal.pone.0083431","article-title":"Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil in adult women","volume":"8","author":"Luna","year":"2013","journal-title":"PloS One"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD015364.pub2-BIB0170|cit170","first-page":"S60","article-title":"Efficacy of quadrivalent HPV 6\/11\/16\/18 vaccine against persistent infection or disease in subjects with prior vaccine HPV type infection","volume":"116","author":"Makhija","year":"2010","journal-title":"Gynecologic Oncology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD015364.pub2-BIB0171|cit171","first-page":"S37","article-title":"Quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against persistent infection or disease in subjects with prior vaccine HPV-type infection","volume":"116","author":"Makhija","year":"2010","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0172|cit172","unstructured":"Clinical study report: long-term follow-up study of safety, immunogenicity, and effectiveness of GARDASIL\u2122 (human papillomavirus [types 6, 11, 16, 18] recombinant vaccine) in mid-adult women - the FUTURE III (females united to unilaterally reduce endo\/ectocervical cancer) study European Medicines Agency"},{"issue":"9679","key":"10.1002\/14651858.CD015364.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial","volume":"373","author":"Munoz","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD015364.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.2018.36.15_suppl.1553","article-title":"Long-term effectiveness and immunogenicity of quadrivalent HPV vaccine in young men: 10-year end-of study analysis","volume":"36","author":"Goldstone","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015364.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"A352","DOI":"10.1136\/sextrans-2011-050119.6","article-title":"Efficacy of the quadrivalent HPV vaccine to prevent anal intraepithelial neoplasia among young men who have sex with men","volume":"87","author":"Goldstone","year":"2011","journal-title":"Sexually Transmitted Infections"},{"issue":"3","key":"10.1002\/14651858.CD015364.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1473-3099(21)00327-3","article-title":"Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Goldstone","year":"2022","journal-title":"Lancet Infectious Diseases"},{"issue":"37","key":"10.1002\/14651858.CD015364.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1016\/j.vaccine.2013.06.057","article-title":"Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males","volume":"31","author":"Goldstone","year":"2013","journal-title":"Vaccine"},{"issue":"4","key":"10.1002\/14651858.CD015364.pub2-BIB0179|cit179","first-page":"357","article-title":"The efficacy of quadrivalent HPV (types 6\/11\/16\/18) vaccine against HPV-related genital disease and infection in HIV negative young men","volume":"6","author":"Hillman","year":"2009","journal-title":"Sexual Health"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0180|cit180","unstructured":"Clinical study report: a study to evaluate the efficacy of GARDASIL\u2122 in reducing the incidence of HPV 6-, 11-, 16-, and 18-related external genital warts, PIN, penile, perianal and perineal cancer, and the incidence of HPV 6-, 11-, 16-, and 18-related genital infection in young men European Medicines Agency"},{"issue":"7","key":"10.1002\/14651858.CD015364.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4161\/hv.7.7.15579","article-title":"Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults","volume":"7","author":"Moreira","year":"2011","journal-title":"Human Vaccines"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD015364.pub2-BIB0182|cit182","first-page":"Abstract SY32","article-title":"Human papillomavirus vaccines in females and males","volume":"71","author":"Palefsky","year":"2011","journal-title":"Cancer Research"},{"issue":"17","key":"10.1002\/14651858.CD015364.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1525-1438.2007.01123.x","article-title":"Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects","volume":"18","author":"Kang","year":"2008","journal-title":"International Journal of Gynecological Cancer"},{"issue":"28","key":"10.1002\/14651858.CD015364.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1016\/j.vaccine.2012.02.079","article-title":"Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females","volume":"30","author":"Li","year":"2012","journal-title":"Vaccine"},{"issue":"12","key":"10.1002\/14651858.CD015364.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.vaccine.2019.01.069","article-title":"Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: a randomized, Phase 3, placebo-controlled study","volume":"37","author":"Mikamo","year":"2019","journal-title":"Vaccine"},{"issue":"6","key":"10.1002\/14651858.CD015364.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/21645515.2015.1008877","article-title":"Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa","volume":"11","author":"Mugo","year":"2015","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0188|cit188","unstructured":"V501 immunogenicity study in females age 9 to 17 years (V501-028) https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00411749 2006"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0189|cit189","unstructured":"Clinical study report: a long term immunogenicity, safety, and effectiveness study of GARDASIL\u2122 (human papillomavirus [types 6,11,16,18] recombinant vaccine) among adolescents who received GARDASIL\u2122 at 9-18 years of age European Medicines Agency"},{"issue":"3","key":"10.1002\/14651858.CD015364.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000253970.29190.5a","article-title":"Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial","volume":"26","author":"Reisinger","year":"2007","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0191|cit191","unstructured":"A clinical trial to study the safety, tolerance and immunogenic response to Gardasil and bivalent rlp2086 vaccine when given at the same time to children between the ages of 11 and 17 https:\/\/clinicaltrials.gov\/show\/NCT01461993 2011"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/INF.0000000000001072","article-title":"Immunogenicity, tolerability and safety in adolescents of bivalent rlp2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine","volume":"35","author":"Senders","year":"2016","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"9574","key":"10.1002\/14651858.CD015364.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD015364.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","article-title":"A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions","volume":"2","author":"Kjaer","year":"2009","journal-title":"Cancer Prevention Research (Philadelphia, Pa.)"},{"issue":"27-28","key":"10.1002\/14651858.CD015364.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet. Oncology"},{"issue":"11","key":"10.1002\/14651858.CD015364.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"British Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD015364.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.vaccine.2018.12.030","article-title":"Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up","volume":"37","author":"Chen","year":"2019","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0199|cit199","first-page":"136","article-title":"Safety and efficacy of a quadrivalent HPV (QHPV) vaccine in Chinese women: results of base study with 30-month follow-up","volume":"27 (Suppl 4)","author":"Chen","year":"2017","journal-title":"International Journal of Gynecological Cancer"},{"issue":"27","key":"10.1002\/14651858.CD015364.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1016\/j.vaccine.2018.08.009","article-title":"Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: a randomized, placebo-controlled trial with 78-month follow-up","volume":"37","author":"Wei","year":"2019","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015364.pub2-BIB0201|cit201","first-page":"S21","article-title":"Long-term efficacy of quadrivalent human papillomavirus vaccine in Chinese women during 10 years of follow-up","volume":"24","author":"Zhao","year":"2020","journal-title":"Journal of Lower Genital Tract Disease"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"100205","DOI":"10.1016\/j.pvr.2020.100205","article-title":"Post-hoc analysis of injection-site reactions following vaccination with quadrivalent human papillomavirus vaccine in Japanese female clinical trial participants","volume":"10","author":"Murata","year":"2020","journal-title":"Papillomavirus Research"},{"issue":"4","key":"10.1002\/14651858.CD015364.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/cas.12106","article-title":"Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years","volume":"104","author":"Yoshikawa","year":"2013","journal-title":"Cancer Science"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"e20194035","DOI":"10.1542\/peds.2019-4035","article-title":"Three-year follow-up of 2-dose versus 3-dose HPV vaccine","volume":"147","author":"Bornstein","year":"2021","journal-title":"Pediatrics"},{"issue":"22","key":"10.1002\/14651858.CD015364.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2016.17615","article-title":"Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women","volume":"316","author":"Iversen","year":"2016","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0206|cit206","unstructured":"Clinical study report: a phase III clinical trial to study the tolerability and immunogenicity of a 2-dose regimen of V503, a multivalent human papillomavirus (HPV) L1 virus-like particle (VLP) vaccine, administered in preadolescents and adolescents (9 to 14 year olds) with a comparison to young women (16 to 26 year olds) Health Canada"},{"issue":"4","key":"10.1002\/14651858.CD015364.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s11427-019-9547-7","article-title":"Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women","volume":"63","author":"Guo","year":"2020","journal-title":"Science China Life Sciences"},{"issue":"2","key":"10.1002\/14651858.CD015364.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jnci\/djz074","article-title":"Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial","volume":"112","author":"Wu","year":"2020","journal-title":"Journal of the National Cancer Institute"},{"issue":"7","key":"10.1002\/14651858.CD015364.pub2-BIB0209|cit209","first-page":"1636","article-title":"Lot-to-lot consistency study of an Escherichia coli-produced bivalent human papillomavirus vaccine in adult women: a randomized trial","volume":"16","author":"Zhao","year":"2019","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"32","key":"10.1002\/14651858.CD015364.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1016\/j.vaccine.2015.06.052","article-title":"Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: a randomized controlled phase 2 clinical trial","volume":"33","author":"Wu","year":"2015","journal-title":"Vaccine"},{"issue":"11","key":"10.1002\/14651858.CD015364.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(21)00453-8","article-title":"Vaccine efficacy against persistent human papillomavirus (HPV) 16\/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study","volume":"22","author":"Basu","year":"2021","journal-title":"Lancet Oncology"},{"issue":"13","key":"10.1002\/14651858.CD015364.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.vaccine.2012.01.058","article-title":"Randomized trial of HPV4 vaccine assessing the response to HPV4 vaccine in two schedules among Peruvian female sex workers","volume":"30","author":"Brown","year":"2012","journal-title":"Vaccine"},{"issue":"39","key":"10.1002\/14651858.CD015364.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"6096","DOI":"10.1016\/j.vaccine.2020.07.030","article-title":"Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages","volume":"38","author":"Chen","year":"2020","journal-title":"Vaccine"},{"issue":"4","key":"10.1002\/14651858.CD015364.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/cid\/ciz887","article-title":"Immunogenicity of 2 and 3 doses of the quadrivalent human papillomavirus vaccine up to 120 months postvaccination: follow-up of a randomized clinical trial","volume":"71","author":"Donken","year":"2019","journal-title":"Clinical Infectious Diseases"},{"issue":"15","key":"10.1002\/14651858.CD015364.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"7832","DOI":"10.1128\/JVI.76.15.7832-7842.2002","article-title":"Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine","volume":"76","author":"Emeny","year":"2002","journal-title":"Journal of Virology"},{"issue":"3","key":"10.1002\/14651858.CD015364.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1097\/INF.0b013e318206c26e","article-title":"Immunogenicity and safety of human papillomavirus-16\/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study","volume":"30","author":"Esposito","year":"2011","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0217|cit217","unstructured":"A randomized, placebo-controlled, phase IIIb HPV vaccination trial with Gardasil\u00ae in patients with recurrent condylomata acuminata https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-004007-13\/DE (accessed on 11 December 2024) 2013"},{"issue":"10","key":"10.1002\/14651858.CD015364.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1089\/jwh.2018.7340","article-title":"Correlates of human papillomavirus vaccination and association with HPV-16 and HPV-18 DNA detection in young women","volume":"28","author":"Feder","year":"2019","journal-title":"Journal of Women's Health"},{"issue":"3","key":"10.1002\/14651858.CD015364.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"e657","DOI":"10.1542\/peds.2013-4144","article-title":"Long-term study of a quadrivalent human papillomavirus vaccine","volume":"134","author":"Ferris","year":"2014","journal-title":"Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD015364.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"pii: e20163947","DOI":"10.1542\/peds.2016-3947","article-title":"4-valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents after 10 years","volume":"140","author":"Ferris","year":"2017","journal-title":"Pediatrics"},{"issue":"11","key":"10.1002\/14651858.CD015364.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/infdis\/jiy743","article-title":"Long-term cross-reactivity against nonvaccine human papillomavirus types 31 and 45 after 2- or 3-dose schedules of the AS04-adjuvanted human HPV-16\/18 vaccine","volume":"219","author":"Folschweiller","year":"2019","journal-title":"Journal of Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD015364.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/CVI.00478-06","article-title":"Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines","volume":"14","author":"Garland","year":"2007","journal-title":"Clinical and Vaccine Immunology"},{"issue":"43","key":"10.1002\/14651858.CD015364.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1016\/j.vaccine.2014.08.011","article-title":"Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults","volume":"32","author":"Giacomet","year":"2014","journal-title":"Vaccine"},{"issue":"8","key":"10.1002\/14651858.CD015364.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1086\/521679","article-title":"Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine","volume":"196","author":"Giuliano","year":"2007","journal-title":"Journal of Infectious Diseases"},{"issue":"18","key":"10.1002\/14651858.CD015364.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.vaccine.2019.03.052","article-title":"Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix\u00ae or Gardasil\u00ae vaccine","volume":"37","author":"Godi","year":"2019","journal-title":"Vaccine"},{"issue":"4","key":"10.1002\/14651858.CD015364.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jnci\/93.4.284","article-title":"Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine","volume":"93","author":"Harro","year":"2001","journal-title":"Journal of the National Cancer Institute"},{"issue":"2","key":"10.1002\/14651858.CD015364.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/CVI.05208-11","article-title":"Immunogenicity of the quadrivalent human papillomavirus (type 6\/11\/16\/18) vaccine in males 16 to 26 years old","volume":"19","author":"Hillman","year":"2012","journal-title":"Clinical and Vaccine Immunology"},{"issue":"9","key":"10.1002\/14651858.CD015364.pub2-BIB0228|cit228","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/jnci\/djac107","article-title":"Performance of cervical screening a decade following HPV vaccination: the Costa Rica vaccine trial","volume":"114","author":"Hu","year":"2022","journal-title":"Journal of the National Cancer Institute"},{"issue":"6","key":"10.1002\/14651858.CD015364.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/INF.0000000000000694","article-title":"An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age","volume":"34","author":"Kosalaraksa","year":"2015","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"21","key":"10.1002\/14651858.CD015364.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","article-title":"Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial","volume":"107","author":"Mao","year":"2006","journal-title":"Obstetrics and Gynecology"},{"issue":"41","key":"10.1002\/14651858.CD015364.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1016\/j.vaccine.2009.07.027","article-title":"Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine","volume":"27","author":"Rowhani-Rahbar","year":"2009","journal-title":"Vaccine"},{"issue":"3","key":"10.1002\/14651858.CD015364.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1128\/CVI.00489-10","article-title":"Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial","volume":"18","author":"Krajden","year":"2011","journal-title":"Clinical and Vaccine Immunology"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.vaccine.2013.09.007","article-title":"Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial","volume":"32","author":"Krajden","year":"2014","journal-title":"Vaccine"},{"issue":"7","key":"10.1002\/14651858.CD015364.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1470-2045(15)00047-9","article-title":"Efficacy of fewer than three doses of an HPV-16\/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials","volume":"16","author":"Kreimer","year":"2015","journal-title":"Lancet Oncology"},{"issue":"8","key":"10.1002\/14651858.CD015364.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/infdis\/jit363","article-title":"Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose","volume":"208","author":"Lamontagne","year":"2013","journal-title":"Journal of Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD015364.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"666","DOI":"10.21149\/10183","article-title":"The effect of a booster dose of HPV tetravalent vaccine after 51 months: implications for extended vaccination schedules","volume":"60","author":"Lazcano-Ponce","year":"2018","journal-title":"Salud Publica de Mexico"},{"issue":"8","key":"10.1002\/14651858.CD015364.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"e015867","DOI":"10.1136\/bmjopen-2017-015867","article-title":"Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials","volume":"7","author":"Lehtinen","year":"2017","journal-title":"BMJ Open"},{"issue":"6","key":"10.1002\/14651858.CD015364.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.vaccine.2013.11.098","article-title":"Randomized controlled trial of two dosing schedules for human papillomavirus vaccination among college-age males","volume":"32","author":"Lin","year":"2014","journal-title":"Vaccine"},{"issue":"19","key":"10.1002\/14651858.CD015364.pub2-BIB0240|cit240","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMcp2108502","article-title":"Human papillomavirus vaccination","volume":"388","author":"Markowitz","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD015364.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/jama.2011.407","article-title":"Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial","volume":"305","author":"Neuzil","year":"2011","journal-title":"Journal of the American Medical Association"},{"issue":"8","key":"10.1002\/14651858.CD015364.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/CVI.00133-15","article-title":"Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine","volume":"22","author":"Nygard","year":"2015","journal-title":"Clinical and Vaccine Immunology"},{"issue":"16","key":"10.1002\/14651858.CD015364.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/jama.2017.1840","article-title":"Immunogenicity of 2 vs 3 doses of the quadrivalent human papillomavirus vaccine in girls aged 9 to 13 years after 60 months","volume":"317","author":"Ogilvie","year":"2017","journal-title":"JAMA"},{"issue":"26","key":"10.1002\/14651858.CD015364.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","article-title":"Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine","volume":"25","author":"Olsson","year":"2007","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"100203","DOI":"10.1016\/j.pvr.2020.100203","article-title":"Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: interim analysis after 8 years of follow-up","volume":"10","author":"Olsson","year":"2020","journal-title":"Papillomavirus Research"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"h4358","DOI":"10.1136\/bmj.h4358","article-title":"Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV vaccine trial","volume":"351","author":"Panagiotou","year":"2015","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD015364.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ijc.25887","article-title":"Long-term persistence of systemic and mucosal immune response to HPV-16\/18 AS04-adjuvanted vaccine in preteen\/adolescent girls and young women","volume":"129","author":"Petaja","year":"2011","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"105-15","DOI":"10.1016\/j.pvr.2017.03.002","article-title":"Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - a combined analysis of five phase III clinical trials","volume":"3","author":"Petersen","year":"2017","journal-title":"Papillomavirus Research"},{"issue":"11","key":"10.1002\/14651858.CD015364.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/infdis\/jix154","article-title":"Sustained immunogenicity of 2-dose human papillomavirus 16\/18 AS04-adjuvanted vaccine schedules in girls aged 9-14 years: a randomized trial","volume":"215","author":"Huang","year":"2017","journal-title":"Journal of Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD015364.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/infdis\/jiw036","article-title":"Randomized open trial comparing 2-dose regimens of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years","volume":"214","author":"Puthanakit","year":"2016","journal-title":"Journal of Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD015364.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jcv.2011.12.009","article-title":"Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine","volume":"53","author":"Rowhani-Rahbar","year":"2012","journal-title":"Journal of Clinical Virology"},{"issue":"7","key":"10.1002\/14651858.CD015364.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.4161\/hv.24340","article-title":"Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial","volume":"9","author":"Safaeian","year":"2013","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"11","key":"10.1002\/14651858.CD015364.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1940-6207.CAPR-13-0203","article-title":"Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial","volume":"6","author":"Safaeian","year":"2013","journal-title":"Cancer Prevention Research (Philadelphia, Pa.)"},{"issue":"32 Pt A","key":"10.1002\/14651858.CD015364.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1016\/j.vaccine.2018.02.087","article-title":"Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study","volume":"36","author":"Sankaranarayanan","year":"2018","journal-title":"Vaccine"},{"issue":"3","key":"10.1002\/14651858.CD015364.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1542\/peds.2014-4199","article-title":"Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and tdap vaccines","volume":"136","author":"Schilling","year":"2015","journal-title":"Pediatrics"},{"issue":"11","key":"10.1002\/14651858.CD015364.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1002\/cam4.1155","article-title":"Ten-year immune persistence and safety of the HPV-16\/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age","volume":"6","author":"Schwarz","year":"2017","journal-title":"Cancer Medicine"},{"issue":"7-8","key":"10.1002\/14651858.CD015364.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1080\/21645515.2019.1625644","article-title":"A ten-year study of immunogenicity and safety of the AS04-HPV-16\/18 vaccine in adolescent girls aged 10-14 years","volume":"15","author":"Schwarz","year":"2019","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/infdis\/jis407","article-title":"Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies","volume":"206","author":"Watson-Jones","year":"2012","journal-title":"Journal of Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD015364.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1097\/INF.0b013e31822d28df","article-title":"Immunogenicity and safety of human papillomavirus-16\/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and\/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial","volume":"30","author":"Wheeler","year":"2011","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"7","key":"10.1002\/14651858.CD015364.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/21645515.2020.1761202","article-title":"Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals","volume":"16","author":"Li","year":"2020","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"8","key":"10.1002\/14651858.CD015364.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1089\/jwh.2009.1753","article-title":"Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women","volume":"19","author":"Zimmerman","year":"2010","journal-title":"Journal of Women's Health"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0262|cit262","unstructured":"Phase 3 trial of a bivalent HPV vaccine (Cecolin\u00ae) in young girls https:\/\/clinicaltrials.gov\/show\/NCT04508309 (accessed on 06 October 2022)"},{"issue":"9","key":"10.1002\/14651858.CD015364.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.vaccine.2024.02.077","article-title":"Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9-14 years of age: interim analysis from a phase 3 clinical trial","volume":"42","author":"Zaman","year":"2024","journal-title":"Vaccine"},{"issue":"2","key":"10.1002\/14651858.CD015364.pub2-BIB0264|cit264","doi-asserted-by":"publisher","first-page":"EVIDoa2300194","DOI":"10.1056\/EVIDoa2300194","article-title":"Immunogenicity of 2 or 3 doses of 9vHPV vaccine in U.S. female individuals 15 to 26 years of age","volume":"3","author":"Berenson","year":"2024","journal-title":"NEJM Evidence"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"e039383","DOI":"10.1136\/bmjopen-2020-039383","article-title":"Transmission reduction and prevention with HPV vaccination (TRAP-HPV) study protocol: a randomised controlled trial of the efficacy of HPV vaccination in preventing transmission of HPV infection in heterosexual couples","volume":"10","author":"MacCosham","year":"2020","journal-title":"BMJ Open"},{"issue":"6","key":"10.1002\/14651858.CD015364.pub2-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/OLQ.0000000000001620","article-title":"Protection to self and to one's sexual partner after human papillomavirus vaccination: preliminary analysis from the Transmission Reduction and Prevention with HPV Vaccination study","volume":"49","author":"MacCosham","year":"2022","journal-title":"Sexually Transmitted Diseases"},{"issue":"12","key":"10.1002\/14651858.CD015364.pub2-BIB0267|cit267","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1038\/s41591-023-02658-0","article-title":"Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results","volume":"29","author":"Barnabas","year":"2023","journal-title":"Nature Medicine"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0268|cit268","unstructured":"Clinical study report: a Phase I\/II study to evaluate the safety and immunogenicity of MEDI-517, a virus-like particle vaccine against human papillomavirus (HPV) types 16 and 18, in healthy adult female volunteers who are HPV-16 or HPV-18 DNA positive https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=580299\/003 (accessed on 06 October 2022)"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0269|cit269","unstructured":"Broad spectrum HPV (human papillomavirus) vaccine in 16 to 26 year old women (V505-001). https:\/\/clinicaltrials.gov\/show\/NCT00520598 https:\/\/clinicaltrials.gov\/show\/NCT00520598 (accessed on 06 October 2022)"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0270|cit270","unstructured":"Prevention and control of neoplasms associated with HPV in high-risk groups in Mexico City: the Condesa Study https:\/\/clinicaltrials.gov\/show\/NCT05149248 (accessed on 06 October 2022)"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0271|cit271","unstructured":"Immunogenicity and safety study of glaxosmithkline (GSK) biologicals' meningococcal vaccine with or without co-administration of Cervarix and Boostrix in female adolescents and young adults https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01755689 (accessed on 20 April 2023)"},{"issue":"27","key":"10.1002\/14651858.CD015364.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1016\/j.vaccine.2018.05.051","article-title":"MenACWY-TT is immunogenic when co-administered with Tdap and AS04-HPV16\/18 in girls and young women: results from a phase III randomized trial","volume":"36","author":"Rivera","year":"2018","journal-title":"Vaccine"},{"issue":"7","key":"10.1002\/14651858.CD015364.pub2-BIB0273|cit273","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(22)00291-1","article-title":"Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial","volume":"23","author":"Shing","year":"2022","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0274|cit274","unstructured":"Clinical Review of Biologics License Application Supplement STN# 125126\/1297.0 \u2013 male indication for GARDASIL Available from: http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM190977.pdf 2009"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/OGX.0000000000001135","article-title":"Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial","volume":"78","author":"Watson-Jones","year":"2023","journal-title":"Obstetrical & Gynecological Survey"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0276|cit276","doi-asserted-by":"publisher","first-page":"2061248","DOI":"10.1080\/21645515.2022.2061248","article-title":"Long-term immunopersistence and safety of the Escherichia coli-produced HPV-16\/18 bivalent vaccine in Chinese adolescent girls","volume":"18","author":"Yao","year":"2022","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0277|cit277","doi-asserted-by":"publisher","first-page":"2052700","DOI":"10.1080\/21645515.2022.2052700","article-title":"The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age","volume":"18","author":"Zhao","year":"2022","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"12","key":"10.1002\/14651858.CD015364.pub2-BIB0278|cit278","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S1473-3099(22)00435-2","article-title":"Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial","volume":"22","author":"Zhao","year":"2022","journal-title":"Lancet Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD015364.pub2-BIB0279|cit279","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/ajco.13833","article-title":"Safety of AS04-HPV-16\/18 vaccine in Chinese women aged 26 years and older and long-term protective effect in women vaccinated at age 18-25 years: a 10-year follow-up study","volume":"19","author":"Zhao","year":"2023","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0280|cit280","doi-asserted-by":"publisher","first-page":"2185456","DOI":"10.1080\/22221751.2023.2185456","article-title":"Safety of hepatitis E vaccination for pregnancy: a post-hoc analysis of a randomized, double-blind, controlled phase 3 clinical trial","volume":"12","author":"Zhong","year":"2023","journal-title":"Emerging Microbes & Infections"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0281|cit281","unstructured":"Adding male single dose HPV vaccination to female HPV vaccination in Tanzania https:\/\/clinicaltrials.gov\/show\/NCT04953130"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.vaccine.2021.11.041","article-title":"Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: the Costa Rica ESCUDDO trial","volume":"40","author":"Porras","year":"2022","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"106592","DOI":"10.1016\/j.cct.2021.106592","article-title":"Design of a Phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men","volume":"115","author":"Giuliano","year":"2022","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0284|cit284","unstructured":"HPV vaccination in Africa - new delivery schedules alias the HANDS HPV vaccine trial https:\/\/clinicaltrials.gov\/show\/NCT03832049"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0285|cit285","unstructured":"ICI-VPH: impact of HPV immunisation schedules against HPV https:\/\/clinicaltrials.gov\/show\/NCT02009800"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0286|cit286","unstructured":"GARDASIL 9: 3 dose vs. 2 dose with delayed 3rd dose https:\/\/clinicaltrials.gov\/show\/NCT03943875"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0287|cit287","unstructured":"Efficacy, immunogenicity and safety of V503 in Chinese women aged 20\u201345 years (V503-023) https:\/\/clinicaltrials.gov\/show\/NCT03998254"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0288|cit288","unstructured":"Efficacy, immunogenicity, and safety study of the 9vHPV vaccine in Japanese males (V503-064) https:\/\/clinicaltrials.gov\/show\/NCT04635423"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0289|cit289","unstructured":"Immunogenicity and safety of the 9-valent human papillomavirus (9vHPV) vaccine in Japanese boys and girls (V503-066) https:\/\/clinicaltrials.gov\/show\/NCT04772534"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0290|cit290","unstructured":"NCT05279248. The immunogenicity and safety of the vaccination of human papillomavirus vaccine and measles-mumps-rubella vaccine https:\/\/clinicaltrials.gov\/study\/NCT05279248"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0291|cit291","unstructured":"Immunogenicity and safety of co-immunization with Cecolin and Hecolin https:\/\/clinicaltrials.gov\/study\/NCT05415345"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0292|cit292","unstructured":"Comparing immune response of 2 vs 3 HPV doses (27-45 years old) https:\/\/clinicaltrials.gov\/study\/NCT05672927"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0293|cit293","unstructured":"Study on the safety and immunogenicity of the immunization procedure for one dose of HPV vaccine https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2300069209"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0294|cit294","unstructured":"Immunogenicity and safety of one dose of HPV vaccine https:\/\/clinicaltrials.gov\/study\/NCT06345885"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0295|cit295","unstructured":"Single-dose HPV vaccination for the prevention of cervical cancer in young adult women in Costa Rica, the PRISMA ESCUDDO trial (PRISMA) https:\/\/clinicaltrials.gov\/study\/NCT05237947"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"211","DOI":"10.21149\/spm.v58i2.7790","article-title":"HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico","volume":"58","author":"Salmeron","year":"2016","journal-title":"Salud Publica de Mexico"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0297|cit297","unstructured":"Adhanom-Ghebreyesus T Cervical Cancer: An NCD We Can Overcome World Health Organization (WHO) 2018 [cited 19 May 2018]. Available from: https:\/\/www.who.int\/dg\/speeches\/detail\/cervical-cancer-an-ncd-we-can-overcome"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0298|cit298","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009069.pub3","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","author":"Arbyn","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD015364.pub2-BIB0299|cit299","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013479","article-title":"Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males","author":"Bergman","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD015364.pub2-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1080\/21645515.2019.1692557","article-title":"Safety of the AS04-adjuvanted human papillomavirus (HPV)-16\/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years","volume":"16","author":"Bi","year":"2020","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00345-008-0302-z","article-title":"Penile cancer: epidemiology, pathogenesis and prevention","volume":"27","author":"Bleeker","year":"2009","journal-title":"World Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1542\/peds.2006-0461","article-title":"Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women","volume":"118","author":"Block","year":"2006","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"Bosch","year":"2002","journal-title":"Journal of Clinical Pathology"},{"issue":"6","key":"10.1002\/14651858.CD015364.pub2-BIB0304|cit304","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"e0128073","DOI":"10.1371\/journal.pone.0128073","article-title":"Incidence patterns and temporal trends of invasive nonmelanotic vulvar tumors in Germany 1999\u20112011: a population-based cancer registry analysis","volume":"10","author":"Buttmann-Schweiger","year":"2015","journal-title":"PloS One"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1467-8519.1989.tb00328.x","article-title":"A report from New Zealand: an \"unfortunate experiment\"","volume":"3","author":"Campbell","year":"1989","journal-title":"Bioethics"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0307|cit307","unstructured":"Cancer Research UK Cervical cancer statistics https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/cervical-cancer"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0308|cit308","unstructured":"Cancer Research UK Cervical cancer incidence by stage at diagnosis https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/cervical-cancer\/incidence#heading-Three2017"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0309|cit309","unstructured":"Cancer Research UK Penile cancer incidence statistics https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/penile-cancer\/incidence#heading-One"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0310|cit310","unstructured":"Cancer Research UK Anal cancer incidence statistics https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/anal-cancer\/incidence#heading-One"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0311|cit311","unstructured":"Cancer Research UK Head and neck cancers incidence statistics https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/head-and-neck-cancers\/incidence#heading-One"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0312|cit312","unstructured":"Cancer Research UK Vaginal cancer incidence statistics https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/vaginal-cancer\/incidence#heading-One"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0313|cit313","unstructured":"Cancer Research UK Vulval cancer incidence https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/vulval-cancer\/incidence"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S2468-2667(17)30222-0","article-title":"Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study","volume":"3","author":"Castanon","year":"2018","journal-title":"Lancet. Public Health"},{"issue":"2","key":"10.1002\/14651858.CD015364.pub2-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani","year":"2012","journal-title":"Research Synththesis Methods"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0316|cit316","unstructured":"Conflict of interest policy for Cochrane Library content, Version 3.6 (2020) https:\/\/training.cochrane.org\/online-learning\/coi-policy\/coi-policy-cochrane-library"},{"issue":"10135","key":"10.1002\/14651858.CD015364.pub2-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(18)30854-7","article-title":"Rapid response to HPV vaccination crisis in Ireland","volume":"391","author":"Corcoran","year":"2018","journal-title":"Lancet"},{"issue":"22","key":"10.1002\/14651858.CD015364.pub2-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1016\/j.vaccine.2017.03.096","article-title":"Two-dose schedules for human papillomavirus vaccine: systematic review and meta-analysis","volume":"35","author":"D'Addario","year":"2017","journal-title":"Vaccine"},{"issue":"2","key":"10.1002\/14651858.CD015364.pub2-BIB0319|cit319","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1006\/gyno.2001.6502","article-title":"Population-based study of squamous cell vaginal cancer: HPV and cofactors","volume":"84","author":"Daling","year":"2002","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015364.pub2-BIB0320|cit320","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/cncr.20365","article-title":"Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer","volume":"101","author":"Daling","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12879-018-3582-y","article-title":"Prevalence and incidence of genital warts and cervical human papillomavirus infections in Nigerian women","volume":"19","author":"Dareng","year":"2019","journal-title":"BMC Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","article-title":"Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study","volume":"15","author":"De Angelis","year":"2014","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD015364.pub2-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"De Martel","year":"2017","journal-title":"International Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD015364.pub2-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/sti.2010.048421","article-title":"Genital warts and cost of care in England","volume":"87","author":"Desai","year":"2011","journal-title":"Sexually Transmitted Infections"},{"issue":"8","key":"10.1002\/14651858.CD015364.pub2-BIB0325|cit325","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/jnci\/djz219","article-title":"Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States, 2001\u20132015","volume":"112","author":"Deshmukh","year":"2020","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0326|cit326","unstructured":"DistillerSR. Version 2.35 Evidence Partners 2021"},{"issue":"17","key":"10.1002\/14651858.CD015364.pub2-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD015364.pub2-BIB0328|cit328","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1001\/jamaoncol.2016.3067","article-title":"Differences in the prevalence of human papillomavirus (HPV) in head and neck squamous cell cancers by sex, race, anatomic tumor site, and HPV detection method","volume":"3","author":"D\u2019Souza","year":"2017","journal-title":"JAMA Oncology"},{"issue":"10316","key":"10.1002\/14651858.CD015364.pub2-BIB0329|cit329","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0330|cit330","unstructured":"What is a serious adverse event? https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0331|cit331","unstructured":"Ferlay J Ervik M Lam F Laversanne M Colombet M Mery L Vagina fact sheet. Global Cancer Observatory: Cancer Today. 2020 Available at https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/22-vagina-fact-sheet.pdf"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0332|cit332","unstructured":"Ferlay J Ervik M Lam F Laversanne M Colombet M Mery L Penis fact sheet. Global Cancer Observatory: Cancer Today. 2020 Available at https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/26-penis-fact-sheet.pdf"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0333|cit333","unstructured":"Ferlay J Ervik M Lam F Laversanne M Colombet M Mery L Anus fact sheet. Global Cancer Observatory: Cancer Today. 2020 Available at https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/10-anus-fact-sheet.pdf"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0334|cit334","unstructured":"Ferlay J Ervik M Lam F Laversanne M Colombet M Mery L Vulva fact sheet. Global Cancer Observatory: Cancer Today. 2020 Available at https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/21-vulva-fact-sheet.pdf"},{"issue":"7","key":"10.1002\/14651858.CD015364.pub2-BIB0335|cit335","doi-asserted-by":"publisher","first-page":"e34874","DOI":"10.2196\/34874","article-title":"Global pattern and trends in penile cancer incidence: population-based study","volume":"8","author":"Fu","year":"2022","journal-title":"JMIR Public Health and Surveillance"},{"issue":"32","key":"10.1002\/14651858.CD015364.pub2-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1016\/j.vaccine.2018.02.003","article-title":"Status of HPV vaccine introduction and barriers to country uptake","volume":"36","author":"Gallagher","year":"2018","journal-title":"Vaccine"},{"issue":"9","key":"10.1002\/14651858.CD015364.pub2-BIB0337|cit337","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1086\/651620","article-title":"Sequential acquisition of human papillomavirus (HPV) infection of the anus and cervix: the Hawaii HPV cohort study","volume":"201","author":"Goodman","year":"2010","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0338|cit338","unstructured":"GSK Study Register https:\/\/www.gsk-studyregister.com\/en\/"},{"issue":"4","key":"10.1002\/14651858.CD015364.pub2-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0340|cit340","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/1743-422X-10-137","article-title":"Detection of specific HPV subtypes responsible for the pathogenesis of condylomata acuminata","volume":"10","author":"Hawkins","year":"2013","journal-title":"Virology Journal"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0341|cit341","unstructured":"Henschke N Bergman H Buckley B Efficacy, effectiveness and immunogenicity of one dose of HPV vaccine compared with no vaccination, 2 doses, or 3 doses Cochrane Response systematic review presented to WHO SAGE. Virtual meeting, WHO Geneva, Switzerland; https:\/\/terrance.who.int\/mediacentre\/data\/sage\/SAGE_Slidedeck_Apr2022.pdf"},{"issue":"11","key":"10.1002\/14651858.CD015364.pub2-BIB0342|cit342","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015363.pub2","article-title":"Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination","author":"Henschke","year":"2025","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0343|cit343","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0344|cit344","unstructured":"Higgins JP Eldridge S Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook."},{"key":"10.1002\/14651858.CD015364.pub2-BIB0345|cit345","first-page":"m2930","article-title":"Association between quadrivalent human papillomavirus vaccination and selected syndromes with autonomic dysfunction in Danish females: population based, self-controlled, case series analysis","volume":"370","author":"Hviid","year":"2020","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0346|cit346","volume-title":"Primary End-Points for Prophylactic HPV Vaccine Trials. IARC Working Group Report","author":"International Agency for Research in Cancer","year":"2014"},{"issue":"11","key":"10.1002\/14651858.CD015364.pub2-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2165\/00019053-200523110-00004","article-title":"Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature","volume":"23","author":"Insinga","year":"2005","journal-title":"PharmacoEconomics"},{"issue":"2","key":"10.1002\/14651858.CD015364.pub2-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1158\/1055-9965.EPI-10-0791","article-title":"Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance","volume":"20","author":"Insinga","year":"2011","journal-title":"Cancer Epidemiology Biomarkers & Prevention"},{"issue":"10","key":"10.1002\/14651858.CD015364.pub2-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Annals of Internal Medicine"},{"issue":"11","key":"10.1002\/14651858.CD015364.pub2-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"e79260","DOI":"10.1371\/journal.pone.0079260","article-title":"Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study","volume":"8","author":"Jaisamrarn","year":"2013","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0351|cit351","unstructured":"Joint Committee on Vaccination and Immunisation (JCVI) Department of Health and Social Care JCVI statement on a one-dose schedule for the routine HPV immunisation programme; 5 August 2022 Available at https:\/\/www.gov.uk\/government\/publications\/single-dose-of-hpv-vaccine-jcvi-concluding-advice\/jcvi-statement-on-a-one-dose-schedule-for-the-routine-hpv-immunisation-programme"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/bmjebm-2018-111012","article-title":"The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias","volume":"23","author":"J\u00f8rgensen","year":"2018","journal-title":"BMJ Evidence Based Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13643-020-01300-1","article-title":"Benefits and harms of the human papillomavirus (HPV) vaccines: comparison of trial data from clinical study reports with corresponding trial register entries and journal publications","volume":"9","author":"J\u00f8rgensen","year":"2020","journal-title":"Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13643-019-0983-y","article-title":"Benefits and harms of the human papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial data from clinical study reports","volume":"9","author":"J\u00f8rgensen","year":"2020","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"k3694","DOI":"10.1136\/bmj.k3694","article-title":"Challenges of independent assessment of potential harms of HPV vaccines","volume":"362","author":"J\u00f8rgensen","year":"2018","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13643-018-0675-z","article-title":"Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review","volume":"7","author":"J\u00f8rgensen","year":"2018","journal-title":"Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD015364.pub2-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/ijc.30900","article-title":"Vulvar cancer in high-income countries: Increasing burden of disease","volume":"141","author":"Kang","year":"2017","journal-title":"International Journal of Cancer"},{"issue":"7-8","key":"10.1002\/14651858.CD015364.pub2-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1080\/21645515.2018.1564436","article-title":"HPV vaccination in a context of public mistrust and uncertainty: a systematic literature review of determinants of HPV vaccine hesitancy in Europe","volume":"15","author":"Karafillakis","year":"2019","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"k3802","DOI":"10.1136\/bmj.k3802","article-title":"Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews","volume":"362","author":"Kirkham","year":"2018","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"24","key":"10.1002\/14651858.CD015364.pub2-BIB0360|cit360","doi-asserted-by":"publisher","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","article-title":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic","volume":"89","author":"Kirnbauer","year":"1992","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"10","key":"10.1002\/14651858.CD015364.pub2-BIB0361|cit361","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1093\/jnci\/djab080","article-title":"Real-world effectiveness of human papillomavirus vaccination against cervical cancer","volume":"113","author":"Kjaer","year":"2021","journal-title":"Journal of the National Cancer Institute"},{"issue":"8","key":"10.1002\/14651858.CD015364.pub2-BIB0362|cit362","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008587.pub2","article-title":"Cytology versus HPV testing for cervical cancer screening in the general population","author":"Koliopoulos","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"19","key":"10.1002\/14651858.CD015364.pub2-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"Journal of the National Cancer Institute"},{"issue":"7","key":"10.1002\/14651858.CD015364.pub2-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1470-2045(15)00047-9","article-title":"Efficacy of fewer than three doses of an HPV-16\/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials","volume":"16","author":"Kreimer","year":"2015","journal-title":"Lancet Oncology"},{"issue":"11","key":"10.1002\/14651858.CD015364.pub2-BIB0365|cit365","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012847","article-title":"Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease","author":"Kyrgiou","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"100174","DOI":"10.1016\/j.pvr.2019.100174","article-title":"HPV vaccination in HIV infection","volume":"8","author":"Lacey","year":"2019","journal-title":"Papillomavirus Research"},{"issue":"6","key":"10.1002\/14651858.CD015364.pub2-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/1471-0528.12459","article-title":"Vulval cancer incidence, mortality and survival in England: age-related trends","volume":"121","author":"Lai","year":"2014","journal-title":"BJOG"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ijgo.12186","article-title":"Progress in HPV vaccination in low- and lower-middle-income countries","volume":"138","author":"LaMontagne","year":"2017","journal-title":"International Journal of Gynaecology and Obstetrics"},{"issue":"4","key":"10.1002\/14651858.CD015364.pub2-BIB0369|cit369","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ijc.31094","article-title":"What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study","volume":"142","author":"Landy","year":"2018","journal-title":"International Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrc.2018.11","article-title":"The molecular landscape of head and neck cancer","volume":"18","author":"Leemans","year":"2018","journal-title":"Nature Reviews Cancer"},{"issue":"14","key":"10.1002\/14651858.CD015364.pub2-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0372|cit372","first-page":"i5078","article-title":"Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry\/journal editor perspective","volume":"355","author":"Lineberry","year":"2016","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0373|cit373","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jaad.2012.12.973","article-title":"Two major pathways of penile carcinogenesis: HPV-induced penile cancers overexpress p16ink4a, HPV-negative cancers associated with dermatoses express p53, but lack p16ink4a overexpression","volume":"69","author":"Mannweiler","year":"2013","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"32 Pt A","key":"10.1002\/14651858.CD015364.pub2-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1016\/j.vaccine.2018.01.057","article-title":"Human papillomavirus vaccine effectiveness by number of doses: systematic review of data from national immunization programs","volume":"36","author":"Markowitz","year":"2018","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0375|cit375","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","article-title":"Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study","volume":"9","author":"McCredie","year":"2008","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD015364.pub2-BIB0376|cit376","first-page":"451","article-title":"The invasive potential of carcinoma in situ of the cervix","volume":"64","author":"McIndoe","year":"1984","journal-title":"Obstetrics and Gynecology"},{"issue":"2","key":"10.1002\/14651858.CD015364.pub2-BIB0377|cit377","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CEJ.0000000000000842","article-title":"Global trends in anal cancer incidence and mortality","volume":"33","author":"Mignozzi","year":"2024","journal-title":"European Journal of Cancer Prevention"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0378|cit378","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejogrb.2023.11.013","article-title":"British Gynaecological Cancer Society (BGCS) vulval cancer guidelines: an update on recommendations for practice 2023","volume":"292","author":"Morrison","year":"2024","journal-title":"European Journal of Obstetrics, Gynecology, and Reproductive Biology"},{"issue":"4","key":"10.1002\/14651858.CD015364.pub2-BIB0379|cit379","first-page":"362","article-title":"The causal link between HPV and cervical cancer and its implications for prevention of cervical cancer","volume":"30","author":"Munoz","year":"1996","journal-title":"Bulletin of the Pan American Health Organization"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0380|cit380","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1136\/ijgc-2021-003274","article-title":"Call for implementation research: cross-continental partnership experiences from the Trans-African Digital e-Health Network (i-STARC Project)","volume":"33","author":"Nasser","year":"2023","journal-title":"International Journal of Gynecologic Cancer"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0381|cit381","unstructured":"NHS Digital Cervical Screening Programme, England - 2019-20: Official statistics, National statistics; November 2020 Available at https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/cervical-screening-annual\/england---2019-20"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0382|cit382","unstructured":"NHS Digital Cervical Screening Programme, England - 2019-20: Official statistics, National statistics: Section 3: Colposcopy; November 2020 Available at https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/cervical-screening-annual\/england---2019-20\/colposcopy"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0383|cit383","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021) Available at https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0384|cit384","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2334-13-39","article-title":"Systematic review of the incidence and prevalence of genital warts","volume":"13","author":"Patel","year":"2013","journal-title":"BMC Infectious Diseases"},{"issue":"9430","key":"10.1002\/14651858.CD015364.pub2-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(04)16674-9","article-title":"The cervical cancer epidemic that screening has prevented in the UK","volume":"364","author":"Peto","year":"2004","journal-title":"Lancet"},{"issue":"21-22","key":"10.1002\/14651858.CD015364.pub2-BIB0386|cit386","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00508-017-1255-2","article-title":"HPV prevalence in vulvar cancer in Austria","volume":"129","author":"Pils","year":"2017","journal-title":"Wiener Klinische Wochenschrift"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0387|cit387","first-page":"g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"2","key":"10.1002\/14651858.CD015364.pub2-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jnci\/djz074","article-title":"Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent Human papillomavirus vaccine: an interim analysis of a randomized clinical trial","volume":"112","author":"Qiao","year":"2020","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0389|cit389","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2025"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0390|cit390","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/pon.6117","article-title":"Attitudes to reducing cervical screening frequency among UK women: a qualitative analysis","volume":"32","author":"Rickford","year":"2023","journal-title":"Psycho-oncology"},{"issue":"3","key":"10.1002\/14651858.CD015364.pub2-BIB0391|cit391","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41416-019-0602-7","article-title":"Human papillomavirus as a driver of head and neck cancers","volume":"122","author":"Sabatini","year":"2020","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0392|cit392","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(15)00414-3","article-title":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","volume":"17","author":"Sankaranarayanan","year":"2016","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0393|cit393","unstructured":"National Cancer Institute and End Results Program Cancer Stat Facts: Anal Cancer Available at https:\/\/seer.cancer.gov\/statfacts\/html\/anus.html"},{"issue":"2","key":"10.1002\/14651858.CD015364.pub2-BIB0394|cit394","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative","volume":"11","author":"Singh","year":"2023","journal-title":"Lancet Global Health"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0395|cit395","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/sextrans-2018-053786","article-title":"Epidemiology of genital warts in the British population: implications for HPV vaccination programmes","volume":"95","author":"Sonnenberg","year":"2019","journal-title":"Sexually Transmitted Infections"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0396|cit396","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/rmv.498","article-title":"Human papillomavirus vaccines","volume":"16","author":"Stanley","year":"2006","journal-title":"Reviews in Medical Virology"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0397|cit397","unstructured":"StataCorp Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC 2017"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0398|cit398","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0399|cit399","first-page":"l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"3","key":"10.1002\/14651858.CD015364.pub2-BIB0400|cit400","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1186\/s12889-018-6268-x","article-title":"Decline in HPV-vaccination uptake in Denmark - the association between HPV-related media coverage and HPV-vaccination","volume":"18","author":"Suppli","year":"2018","journal-title":"BMC Public Health"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0402|cit402","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jclinepi.2020.11.003","article-title":"Machine learning reduced workload with minimal risk of missing studies: development and evaluation of a randomized controlled trial classifier for Cochrane Reviews","volume":"133","author":"Thomas","year":"2021","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD015364.pub2-BIB0403|cit403","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/aje\/kwz284","article-title":"Hospital records of pain, fatigue, or circulatory symptoms in girls exposed to human papillomavirus vaccination: cohort, self-controlled case series, and population time trend studies","volume":"189","author":"Thomsen","year":"2020","journal-title":"American Journal of Epidemiology"},{"issue":"49","key":"10.1002\/14651858.CD015364.pub2-BIB0404|cit404","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1016\/j.vaccine.2023.11.010","article-title":"Adverse events from HPV vaccination in Taiwan","volume":"41","author":"Tsai","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"10.1002\/14651858.CD015364.pub2-BIB0405|cit405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.1986333","article-title":"Changing trends in HPV vaccination in Japan","volume":"18","author":"Ujiie","year":"2022","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"4","key":"10.1002\/14651858.CD015364.pub2-BIB0406|cit406","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.adaj.2019.10.010","article-title":"Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines: Umbrella review of systematic reviews","volume":"151","author":"Villa","year":"2020","journal-title":"Journal of the American Dental Association"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0407|cit407","first-page":"241","article-title":"Human papillomavirus vaccines: WHO position paper, May 2017","volume":"92","author":"World Health Organization","year":"2017","journal-title":"Weekly Epidemiological Record"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0408|cit408","unstructured":"World Health Organization Cervical cancer Available at http:\/\/www.who.int\/cancer\/prevention\/diagnosis-screening\/ cervical-cancer\/en\/"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0409|cit409","unstructured":"World Health Organization WHO cervical cancer screening coverage data Previously available at https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/coverage-of-national-cervical-cancer-screening-program-(-)"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0410|cit410","unstructured":"World Health Organization List of prequalified vaccines Available at https:\/\/extranet.who.int\/pqweb\/vaccines\/list-prequalified-vaccines"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0411|cit411","unstructured":"World Health Organization WHO updates recommendations on HPV vaccination schedule; December 2022 Available at https:\/\/www.who.int\/news\/item\/20-12-2022-WHO-updates-recommendations-on-HPV-vaccination-schedule"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0412|cit412","unstructured":"Global strategy to accelerate the elimination of cervical cancer as a public health problem; November 2020 Available at https:\/\/www.who.int\/publications\/i\/item\/9789240014107"},{"issue":"11","key":"10.1002\/14651858.CD015364.pub2-BIB0413|cit413","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1080\/21645515.2016.1199308","article-title":"Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16\/18 AS04-adjuvanted vaccine in the United Kingdom","volume":"12","author":"Willame","year":"2016","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"7","key":"10.1002\/14651858.CD015364.pub2-BIB0414|cit414","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1080\/21645515.2020.1756670","article-title":"Multidimensional social and cultural norms influencing HPV vaccine hesitancy in Asia","volume":"16","author":"Wong","year":"2020","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"6","key":"10.1002\/14651858.CD015364.pub2-BIB0415|cit415","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/sextrans-2011-050073","article-title":"The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK","volume":"87","author":"Woodhall","year":"2011","journal-title":"Sexually Transmitted Infections"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0416|cit416","unstructured":"World Bank Country and Lending Groups Available at https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0417|cit417","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.04.018","article-title":"Development of the summary of findings table for network meta-analysis","volume":"115","author":"Yepes-Nu\u00f1ez","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015364.pub2-BIB0418|cit418","first-page":"m4931","article-title":"Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study","volume":"372","author":"Yoon","year":"2021","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"11","key":"10.1002\/14651858.CD015364.pub2-BIB0419|cit419","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1177\/0956462419852224","article-title":"Safety and efficacy of human papillomavirus vaccination for people living with HIV: a systematic review and meta-analysis","volume":"30","author":"Zhan","year":"2019","journal-title":"International Journal of STD & AIDS"},{"issue":"5","key":"10.1002\/14651858.CD015364.pub2-BIB0420|cit420","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015364","article-title":"Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis","author":"Bergman","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:53:03Z","timestamp":1790218383000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015364.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":420,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015364.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]}}}